Alzamend Neuro revised the deal from up to $25 million to $10 million, including $2.5 million more cash. The cash helps, but preferred shares can become common shares and missed filing dates can trigger cash payments, so the facts point in different directions.
The added cash can help pay for Alzamend's work. But preferred shares can become common shares, shrinking existing owners' portions. The company may also owe cash if it misses share-filing deadlines. These facts point in different directions.
Follow Alzamend Neuro, Inc. (ALZN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ALZN